Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
沃拉西尼联合肿瘤特异性肽 PEP-IDH1M 疫苗治疗复发性突变 IDH1 胶质瘤患者的临床评价和无创监测
基本信息
- 批准号:10419216
- 负责人:
- 金额:$ 39.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAutomationAutomobile DrivingBloodBrainBrain NeoplasmsCancer Therapy Evaluation ProgramClinicalClinical TrialsCommon Terminology Criteria for Adverse EventsDevelopmentDigital Imaging and Communications in MedicineEffectivenessEnzymesEvaluationEventFutureGenesGliomaGliomagenesisGoalsImageImmuneImmunologicsImmunosuppressionImmunotherapeutic agentImpairmentInfrastructureIsocitrate DehydrogenaseLeadMagnetic Resonance ImagingMagnetic Resonance SpectroscopyManufacturer NameMapsMeasurementMeasuresMediatingMethodsMissionMonitorMorbidity - disease rateMutationNeurologicOncogenicOutcomePatientsPeptide VaccinesPhaseProgression-Free SurvivalsProteinsProtocols documentationQuality of lifeRecurrenceReportingResearchRoleSafetySerumSerum MarkersSignal TransductionSpeedStandardizationT cell responseT-Cell ActivationT-LymphocyteTechniquesTherapeuticToxic effectTranslatingTranslationsTumor Specific PeptideVaccine TherapyVaccinesValidationWorkbasecell killingcell mediated immune responseclinical decision-makingclinical research sitecombinatorialcomputerized data processingdesigndiagnostic biomarkerdiagnostic technologiesearly phase clinical trialexperiencefightingfirst-in-humanhuman studyimage guided interventionimmunogenicimprovedinhibitorinhibitor therapymagnetic resonance spectroscopic imagingmortalitymutantneoplastic cellnew therapeutic targetnon-invasive monitornovelnovel anticancer drugnovel diagnosticsnovel therapeuticspatient tolerabilityphase I trialpublic health relevanceradiological imagingresearch clinical testingresponsestandard of caresupport toolstargeted treatmenttooltreatment strategytumortumor diagnosistumorigenesisvaccine development
项目摘要
Abstract – The identification of mutations in the isocitrate dehydrogenase 1 (mIDH1) gene has led to significant
advances in understanding lower grade gliomas. Lower grade gliomas, WHO grade II-III, can have a longer
median overall survival than WHO grade IV, yet they still develop significant neurological morbidity and ultimately
mortality, as standard of care therapies are not curative. New therapeutics are needed to target lower grade
gliomas to improve quality of life outcomes and survival for these patients. The mIDH1 mutation exists in over
70% of glioma subtypes and is the oncogenic driver in lower grade gliomas by leading to the extreme
overproduction of the oncometabolite R-2-hydroxyglutarate (2HG). Because the mutation is specific to the tumor,
it provides significant targets for the development of: 1) targeted therapeutics, such as mIDH1/2 inhibitors and
immunotherapeutic vaccines (e.g., vorasidenib and PEPIDH1M, respectively) and 2) non-invasive tumor diagnosis
and monitoring methods, via magnetic resonance spectroscopy (MRS). More recently, it has been reported that
in addition to driving the oncogenesis of lower grade gliomas, 2HG has immunosuppressive actions. Its role as
a driver of gliomagenesis and now induction of immunosuppression of tumor-fighting T-cells places 2HG as a
critical target in fighting lower grade gliomas. Thus, we propose a clinical trial for a combined therapy of
vorasidenib and PEPIDH1M. We hypothesize that early suppression of 2HG by vorasidenib would allow
subsequent or concurrent administration of PEPIDH1M vaccine to generate a more robust T-cell response and
lead to increased immune-mediated tumor cell kill (Specific Aim 1). In this phase I, single-site clinical trial, we
will determine the safety of this combinatorial approach. Toxicity events will be evaluated and graded by CTCAE
5.0 criteria. The RANO criteria will be used to assess radiographic progression-free survival based on routine
MRI imaging. As an exploratory goal, we will map 2HG across the brain longitudinally using existing high-speed
magnetic resonance spectroscopic imaging (MRSI) and offline processing to monitor the effects of vorasidenib
(Specific Aim 2). Finally, in parallel with the clinical trial, we will convert the validated 2HG mapping tool into a
standardized works-in-progress (WIP) package for reporting 2HG levels on both GE and Siemens scanner
DICOM workflow (Specific Aim 3). This project builds on 1) our previous experiences participating in the early
clinical trials for PEPIDHM1 and vorasidenib, where we also characterized longitudinal 2HG levels, and 2) our
decades-long experience with automating MRS methods and translating them into manufacturer supported WIP
packages.
摘要 – 异柠檬酸脱氢酶 1 (mIDH1) 基因突变的鉴定已导致显着的
在了解低级别神经胶质瘤方面取得了进展。较低级别的神经胶质瘤,即 WHO II-III 级,可以有更长的时间
中位总生存率高于 WHO IV 级,但他们仍然出现显着的神经系统发病率,最终
死亡率,因为标准护理疗法无法治愈。需要新的治疗方法来针对较低级别
神经胶质瘤,以改善这些患者的生活质量和生存率。 mIDH1 突变存在于超过
70% 的神经胶质瘤亚型,是低级别神经胶质瘤的致癌驱动因素,通过导致极端
致癌代谢物 R-2-羟基戊二酸 (2HG) 的过量产生。因为突变是肿瘤特有的,
它为以下方面的开发提供了重要的目标:1) 靶向治疗,例如 mIDH1/2 抑制剂和
免疫治疗疫苗(例如,分别为 vorasidenib 和 PEPIDH1M)和 2) 非侵入性肿瘤诊断
和监测方法,通过磁共振波谱(MRS)。近日,有报道称
除了促进低级别神经胶质瘤的肿瘤发生外,2HG 还具有免疫抑制作用。其作用为
神经胶质瘤发生的驱动因素,现在诱导抗肿瘤 T 细胞的免疫抑制,使 2HG 成为一种
对抗低级别神经胶质瘤的关键目标。因此,我们建议进行一项联合治疗的临床试验
沃拉西尼和 PEPIDH1M。我们假设 vorasidenib 早期抑制 2HG 将允许
随后或同时施用 PEPIDH1M 疫苗以产生更强大的 T 细胞反应,并且
导致免疫介导的肿瘤细胞杀伤增加(具体目标 1)。在这个 I 期单中心临床试验中,我们
将决定这种组合方法的安全性。毒性事件将由CTCAE进行评估和分级
5.0标准。 RANO 标准将用于根据常规评估影像学无进展生存期
核磁共振成像。作为探索性目标,我们将利用现有的高速在大脑中纵向绘制 2HG
磁共振波谱成像 (MRSI) 和离线处理来监测沃拉西尼的效果
(具体目标 2)。最后,在临床试验的同时,我们会将经过验证的 2HG 绘图工具转换为
标准化在制品 (WIP) 包,用于报告 GE 和西门子扫描仪上的 2HG 水平
DICOM 工作流程(具体目标 3)。该项目建立在 1) 我们之前参与早期项目的经验基础上
PEPIDHM1 和 vorasidenib 的临床试验,其中我们还表征了纵向 2HG 水平,以及 2) 我们的
在自动化 MRS 方法并将其转化为制造商支持的 WIP 方面拥有数十年的经验
包。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KATHERINE B PETERS其他文献
KATHERINE B PETERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KATHERINE B PETERS', 18)}}的其他基金
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
沃拉西尼联合肿瘤特异性肽 PEP-IDH1M 疫苗治疗复发性突变 IDH1 胶质瘤患者的临床评价和无创监测
- 批准号:
10707909 - 财政年份:2022
- 资助金额:
$ 39.27万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 39.27万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 39.27万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 39.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 39.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 39.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




